177 related articles for article (PubMed ID: 31773233)
1. Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy.
Sörensen A; Carles M; Bunea H; Majerus L; Stoykow C; Nicolay NH; Wiedenmann NE; Vaupel P; Meyer PT; Grosu AL; Mix M
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1056-1064. PubMed ID: 31773233
[TBL] [Abstract][Full Text] [Related]
2. Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
Zschaeck S; Zöphel K; Seidlitz A; Zips D; Kotzerke J; Baumann M; Troost EGC; Löck S; Krause M
Radiother Oncol; 2021 Feb; 155():204-211. PubMed ID: 33252044
[TBL] [Abstract][Full Text] [Related]
3. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
5. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
6. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.
Wiedenmann NE; Bucher S; Hentschel M; Mix M; Vach W; Bittner MI; Nestle U; Pfeiffer J; Weber WA; Grosu AL
Radiother Oncol; 2015 Oct; 117(1):113-7. PubMed ID: 26432067
[TBL] [Abstract][Full Text] [Related]
7. FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
Zschaeck S; Löck S; Leger S; Haase R; Bandurska-Luque A; Appold S; Kotzerke J; Zips D; Richter C; Gudziol V; Schreiber A; Zöphel K; Baumann M; Krause M
Radiother Oncol; 2017 Mar; 122(3):437-444. PubMed ID: 28222892
[TBL] [Abstract][Full Text] [Related]
8. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.
Hentschel M; Appold S; Schreiber A; Abolmaali N; Abramyuk A; Dörr W; Kotzerke J; Baumann M; Zöphel K
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1203-11. PubMed ID: 21350962
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
Komar G; Lehtiö K; Seppänen M; Eskola O; Levola H; Lindholm P; Sipilä H; Seppälä J; Grénman R; Solin O; Minn H
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2042-50. PubMed ID: 24898846
[TBL] [Abstract][Full Text] [Related]
10. Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [
Crispin-Ortuzar M; Apte A; Grkovski M; Oh JH; Lee NY; Schöder H; Humm JL; Deasy JO
Radiother Oncol; 2018 Apr; 127(1):36-42. PubMed ID: 29273260
[TBL] [Abstract][Full Text] [Related]
11. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
[TBL] [Abstract][Full Text] [Related]
12. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
[TBL] [Abstract][Full Text] [Related]
13. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
Kazmierska J; Cholewinski W; Piotrowski T; Sowinska A; Bak B; Cegła P; Malicki J
Br J Radiol; 2020 Feb; 93(1106):20180781. PubMed ID: 31860336
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y
Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072
[TBL] [Abstract][Full Text] [Related]
17. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
18. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
[TBL] [Abstract][Full Text] [Related]
19. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
20. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
